Jasper Therapeutics (JSPR) Net Income towards Common Stockholders (2020 - 2025)

Jasper Therapeutics' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$16.0 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders rose 35.08% year-over-year to -$16.0 million; the TTM figure through Dec 2025 stood at -$82.8 million (down 9.83% YoY), while the FY2025 annual figure was -$84.0 million, down 17.81% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$16.0 million, up from -$18.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $11.9 million in Q3 2022, with the low at -$26.7 million in Q2 2025.
• The 5-year median for Net Income towards Common Stockholders is -$14.4 million (2022), against an average of -$13.5 million.
• The sharpest annual moves came in 2021 and 2022: Net Income towards Common Stockholders sank 782.64% in 2021, then surged 448.77% in 2022.
• Jasper Therapeutics' Net Income towards Common Stockholders stood at -$9.1 million in 2021, then plunged by 57.28% to -$14.2 million in 2022, then slipped by 17.77% to -$16.8 million in 2023, then slumped by 46.88% to -$24.6 million in 2024, then surged by 35.08% to -$16.0 million in 2025.
• Business Quant data shows JSPR's Net Income towards Common Stockholders at -$16.0 million in Q4 2025, -$18.9 million in Q3 2025, and -$26.7 million in Q2 2025.